Stockreport

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadershi [Read more]